Anthony J. Olszanski, Jessica R. Bauman, Hannah Kinder, Margaret von Mehren, Teresa LEE, Hossein Borghaei, Namrata Vijayvergia, Michael J. Hall, Khushbukhat Khan, Umar Hayat, Dario C. Altieri. "A phase 1, first-in-human, open-label, dose-escalation and -expansion study of gamitrinib, a first-in-class, mitochondria-directed inhibitor of the molecular chaperone heat shock protein-90 (Hsp90) in patients with advanced cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps3180